



OPEN ACCESS

Key Words

Ultrasonography, breast cancer, axillary lymph node

Corresponding Author

Manmeet Kaur,
Department of Surgery, G.M.C.,
Jammu, Jammu City, Jammu and
Kashmir, India
drmanmeetkaur79@gmail.com

Author Designation

^{1,2}Associate Professor

³MCh Surgical Oncology Resident

⁴Lecturer

Received: 22 November 2023

Accepted: 14 December 2023

Published: 15 December 2023

Citation: D. Nitinkumar Chaudhari, Manish Nagendra, Shahir Merchant and Manmeet Kaur, 2023. The Clinical Impact of Ultrasound in Detecting Axillary Metastasis in Breast Cancer Patients without Apparent Axillary Disease: A Study on Effectiveness. Res. J. Med. Sci., 17: 346-351, doi: 10.59218/makrjms.2023.12.346.351

Copy Right: MAK HILL Publications

The Clinical Impact of Ultrasound in Detecting Axillary Metastasis in Breast Cancer Patients without Apparent Axillary Disease: A Study on Effectiveness

¹Nitinkumar Chaudhari, ²Manish Nagendra, ³Shahir Merchant and ⁴Manmeet Kaur

¹Department of General Surgery, Ananta Institute of Medical Sciences and Research Centre, Dist-Siyol, Rajasthan, India

²Department of Microbiology, N.S.C.B., Medical College, Jabalpur, Madhya Pradesh, India

³Department of Surgical Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India

⁴Department of Surgery, G.M.C., Jammu, Jammu City, Jammu and Kashmir, India

ABSTRACT

The goal of performing preoperative ultrasonography on breast cancer patients who do not have clinical axillary illness is to find axillary lymph node metastases as reliably as possible. But it's important to test how well ultrasound can detect axillary illness. Research participants were 400 women who had treatment for invasive breast cancer at tertiary care cancer institute. When it came time for staging, every patient had an ipsilateral axillary ultrasound. In addition to analyzing the preoperative ultrasonography descriptively the results of the cohort were compared with their corresponding histology and cytology data. All statistical analysis was carried out using SPSS V 22. The axillary ultrasound diagnostic index was determined with the following values sensitivity at 31.9%, specificity at 81.4%, positive predictive value (PPV) at 36.9%, negative predictive value (NPV) at 80.2% and an overall diagnostic accuracy of 70.4%. Among the patients, ductal invasive breast carcinoma emerged as the predominant histological type, accounting for 78.5% and T2 staging was assigned to 50.75% of the tumors. Patients with breast cancer who did not have any visible signs of axillary disease were not able to have their nodal status determined by axillary ultrasound in this study.

INTRODUCTION

Breast cancer is a significant worldwide health concern that necessitates accurate detection techniques for efficient treatment and better patient outcomes. The involvement of axillary lymph nodes is a crucial factor in breast cancer staging that dramatically affects treatment choices and prognostic evaluations^[1]. Personalized treatment approaches must take into account the precise identification of axillary metastases yet, early symptoms of axillary illness may not always be detected by traditional clinical examinations. Advanced imaging technologies, especially ultrasound, have become indispensable tools in the therapy of breast cancer due to this diagnostic problem^[2]. A thorough evaluation of the axilla is required because nodal metastasis is present in (20-40%)^[3] of patients with non-palpable axillary disease and it is one of the most significant prognostic factors in the managements of primary breast cancers. As a result, axillary ultrasounds has become a useful tool for identifying patients who are at risk of nodal involvement^[4,5]. Variations in echogenicity, sizes, shapes or boundaries, lack of homogeneity, changes in cortical thickness and loss of fatty hilum on grayscale examination are among the ultrasound findings associated with malignant lymph nodes. A suspicious lymph node's Doppler study may reveal anomalies in the vascular pattern^[6].

In order to detect axillary metastases in breast cancer patients who do not exhibit obvious axillary illness upon clinical examination, this introduction aims to investigate the clinical use of ultrasonography. We want to uncover the importance of ultrasonography in early identification, how it shapes individualized treatment plans and how it directs focused approaches as we explore its many uses^[7]. Beyond these technical aspects the introduction also highlights how ultrasonography can help patients with breast cancer live better lives generally and lessen the burden of morbidity. The American College of Surgeons Oncology Group (ACOSOG) study Z0011 recently produced practice-changing results that eliminate the need for axillary lymph node dissection (ALND) in patients with clinical T1-T2 tumors treated with breast-conserving therapy and fewer than three metastasized axillary lymph nodes^[8]. In this patient subgroup, radiation was found to be a preferable option to ALND according to the results of the AMAROS study. The effectiveness of preoperative fine needle aspiration biopsy (FNAB) as a less invasive axillary technique and axillary ultrasonography was questioned in these studies its applicability in Mexico is still unclear^[9].

Aims and objective: The Clinical Impact of Ultrasound in Detecting Axillary Metastasis in Breast Cancer Patients without Apparent Axillary Disease a Study on Effectiveness.

MATERIALS AND METHODS

We included 400 women who were diagnosed with cancer and treated at tertiary care cancer institute. We retrieved the information from patient's medical records. Using the TNM (tumor, node and metastasis) staging approach, all patients were categorized. Every patient's demographic and clinical details were meticulously documented. A clinical evaluation was a part of the diagnostic process. All patients also have axillary ultrasounds using the Aloka ProSound Alpha 7 system, which has a frequency range of 13.3-3.61 MHz, a 38 mm linear transducer, and other advanced technology. Axillary ultrasonography results were classified as "suspicious" or "non-suspicious" based on 3 factors lymph node shape, fatty hilum presence and cortical bone thickness. Patients were only asked to undergo FNAB prior to surgery if their ultrasound readings were abnormal. After a mastectomy, macrometastases, also known as pN1a disease, were defined as clusters of malignant cells larger than 0.2 mm in the lymph nodes that were removed. When it came to histology the results were considered definitive.

We have descriptive statistics, sensitivity, specificity, PPV, NPV, FN, FP and accuracy. Analyzing the categorical data between the disparities of ultrasonography findings and the histopathology reports, chi-square tests were utilized. We computed the positive and negative likelihood ratios as well as the diagnostic odds ratio (OR) with a 95% confidence interval (CI). The link between suspicious sonographic features and metastatic lymph nodes was identified using a logistic regression model. The level of statistical significance was established at $p < 0.05$. All statistical analysis was carried out using SPSS V 22.

RESULTS

Invasive breast cancer and non-palpable axillary illness were detected in 400 women who had treatment between 2020 and 2023. This study does not include patients who have recently had neoadjuvant chemotherapy. Females (mean age 53.8) who had not yet entered menopause made up the bulk. For 78.5% of patients the histology was ductal invasive breast carcinoma and for 50.75 percent of tumors, the stage was T2. Table 1 displays the demographic and tumor features. Clinical characteristics of the patients and biological characteristics of the primary breast tumor (Table 1) shows that 89 patients or 22.25 percent, had ultrasound-confirmed suspicious lymph nodes. According to the final axillary histology, 93 out of 400 women who underwent breast surgery and had axillary treatment discovered metastatic lymph nodes (Table 2). True positive cases (TP) constitute the 31




Fig. 1: Graphical representation of distribution of age in years




Fig. 2: Distribution of respondents based on their histology




Fig. 3: Distribution of respondents based on Tumor

patients out of 84 who had worrisome axillary ultrasonography and whose axillary histology revealed subsequent metastasis false-positive cases (FP) constitute the 53 patients who did not show any metastasis. Contrarily, out of 316 patients whose axillary ultrasounds came back negative, 62 (true-negative cases TN) had metastases confirmed by histology and 254 (FN) had no such findings. "Sensitivity (Sen) Specificity (Spe) Predictive Positive Value (PPV) Negative Predictive Value (NPV) and Diagnostic Accuracy (DA)."

DISCUSSION

Author chose the population between the age of 20 to over 60 Years, in which the age group 41-50 shows the highest number of Patient and the age




Fig. 4: Distribution of respondents based on clinical stage

group 20-30 shows the least number of Patient. The most of the cases i.e. 37 (52.86%) presented within 4-6 months of onset of their illness. Least number of cases were found to have duration more than 9 months of their illness. The patients presented with breast lump. Most of the carcinoma breast cases 84.29 % present with lump only. Least common presentation is lump with nipple discharge 7.14%.

A thorough evaluation of the axilla is necessary^[10]. "But there are certain drawbacks, such as a large variation in explorers a lack of accuracy in assessing axillary lymph nodes and a reduced sensitivity to a higher concentration of adipose tissue, which can lead to false negatives in the clinical axillar evaluation of up to 40%^[11]. The National Cancer Institute of is among the oncological institutes with significant expertise in axillary clinical examination, with an incidence of 24% for axillary lymph node metastases. However, there is a need for complementary strategies in this area. Axillary ultrasonography prior to surgery is now standard practice for the diagnosis of breast cancer, according to clinical guidelines. The high morbidity surgery ALND is avoided by patients with non-suspicious ultrasonography thanks to SLNB. Axillary ultrasonography, on the other hand, directs FNAB of worrisome axillary lymph nodes in the direction of accurate disease staging and treatment alterations. However, there is a lack of consensus within the literature about the diagnostic precision and practicality of axillary ultrasound^[12,13].

According to multiple studies, axillary ultrasonography has a sensitivity of 7.4-95% and a specificity of 44-100% when it comes to detecting metastases in the axillary lymph nodes^[14,15]. At 96.3% specificity and 18.2% sensitivity in 2008 the group studied by Cowher *et al.* We found a sensitivity of 31.9%^[16]. It was determined that ultrasound did not have enough diagnostic accuracy to identify metastases in this patient cohort. There is definitely space for progress in this area however, axillary ultrasound will not achieve 100% sensitivity or PPV. Many studies have excluded individuals without ultrasonographic signs suggestive for metastasis but have not excluded patients with neoadjuvant

Table 1: Characteristics of axillary lymph nodes observed by ultrasound

Variables	Sonographic characteristics Suspicious of metastasis		No suspicious of metastasis		Total	
	n	Percentage	n	Percentage	n	Percentage
Axillary ultrasound	89	22.25	311	77.75	400	100
Cortical of lymph node						
Diffuse cortical thickening	6	1.5	2	0.5	8	2
Focal cortical thickening	23	5.75	2	0.5	25	6.25
Simple cortical thickening	44	11	5	1.25	49	12.25
Without cortical thickening	8	(1.9)	310	77.5	318	79.4
Total	81	18.25	319	79.75	400	100
Fatty hilum of the lymph node						
Loss of the fatty hilum	17	4.25	0	(0)	17	4.25
Unconventionality of the fatty hilum	19	4.75	0	(0)	19	4.75
Normal fatty hilum	49	12.25	315	78.75	364	91
Total	85	21.25	315	78.75	400	100
Lymph node shape						
Not preserved	22	5.5	2	0.5	24	6
Conserved	61	15.25	315	78.75	376	94
Total	83	20.75	317	79.25	400	100

Table 2: The results of the axillary lymph node histopathological examination and the axillary ultrasound are summarized in this contingency table

Axillary ultrasound	Histopathological study		Total
	Positive	Negative	
Suspicious of metastasis	31	53	84
No suspicious of metastasis	62	254	316
Total	93	307	400

Table 3: Diagnostic indices of the alteration of each one of the characteristics of the axillary lymph nodes obtained by ultrasound

	Evaluation of the criteria of the ultrasound study				
	Sens	Spes	PPVs	NPVs	Das
Diffuse cortical thickening	3.9	97.8	39.5	77.9	76.8
Focal cortical thickening	11.2	93.8	34.8	78.2	75.1
Simple cortical thickening	19.5	86.4	31.2	77.5	71.5
Loss of the fatty hilum	10.9	96.8	59.7	76.5	75.3
Unconventionality of the fatty hilum	4.8	94.7	22.8	76.8	74.8
Not preserved shape	11.2	95.1	43.5	76.2	74.7

Data are presented as %

Table 4: Diagnostic indices of the alteration of each one of the characteristics of the axillary lymph nodes obtained by ultrasound

	Evaluation criteria of the axillary ultrasound study						
	Cortical	Hilum	Shapes	Cortical+Hilums	Cortical+Shapes	Hilum+Shapes	Hilum+Shape+Corticals
Sen	28.9	14.8	11.2	14.2	9.8	7.8	6.48
Spe	79.8	92.8	94.8	91.8	95.2	96.8	97.2
PPV	34.4	41.5	43.7	37	38.2	54.8	49.5
NPV	79.5	78.1	78.5	78.5	79.4	77.2	79.1
DA	69.2	75.2	76.4	74.9	76.8	16.8	76.9

Data are presented as %

Table 5: Diagnostic indices of axillary ultrasound and fine needle aspiration biopsy for the diagnostic of axillary metastasis in patients with breast cancer

Diagnostic index	Axillary ultrasound	Fine needle aspiration
Sensitivity	31.9	73.8
Specificity	81.4	92.8
Positive predictive value	36.9	86.8
Negatives predictive values	80.2	86.2
Diagnostics accuracy	70.4	85.4

treatment, hence data on the specificity of axillary ultrasonography are rare^[17,18]. According to this data, the specificity value is 82.5%. The current study found that axillary ultrasonography had a positive predictive value of 37.1%. Because of this, we cannot use this value to confirm the presence of metastasis. Nevertheless, we were able to assume a low likelihood of metastasis due to the negative predictive value of 79.6%. For this reason the idea that SLNB can go undetected in individuals with normal axillary ultrasonography is a significant one. The majority of these patients, according to the latest findings, will have a minimal tumor disease burden when it comes

to axillary lymph node metastases^[19]. Ultrasound has a poor diagnostic accuracy of 70.4% in our data, with the large negative predictive value being the main culprit.

A large number of false-positive cases (62.8%) were detected by axillary ultrasonography. Plus, just 26.3% of patients who underwent FNAB after a worrisome ultrasound actually found metastases. Because of these findings, more caution should be exercised in the use of ultrasound for preoperative assessment and in the selections of patients for FNABs however, all patients will undergo evaluation by SLNBs and if required, ALNDs. I intend to go. In order to avoid a dual surgical procedure a larger financial

impact and a lengthier hospital stay, it is crucial to emphasize the significance of high-sensitivity ultrasound findings when referring patients with extensive axillary diseases to FNAB as they will help determine which patients will definitely require ALNDs and which ones can forego SLNB^[20].

According to Whitman *et al.* the likelihood of metastasis increases when the size of the lymph node is bigger than 2 cm. A study conducted in 2013 by More *et al.* with 110 women found that axillary nodes that did not have metastases were larger than those that did^[21,22]. It is likely that the axillary ultrasound reports did not include the size of the lymph nodes since this finding was deemed to have low sensitivity for the identification of metastases in axillary lymph nodes. Lymph node change is associated with the morphological abnormalities. According to multiple studies, cortical thickness of more than 2 mm is the first sign of metastasis in lymph nodes. Our research did not find any correlation between axillary illness and cerebral morphologic alterations^[11,18]. The most crucial morphological findings for lymph node metastasis, according to Nori *et al.*, was the disappearance of the fatty hilum. This finding was consistent with our investigation and it was even more accurate than cortical thickening (83.3% vs. 35%)^[22,23]. Lymphoid hyperplasia was linked to the irregular shape of the fatty hilum. A higher probability of axillary metastasis was associated with loss of fatty hilum, which the only ultrasound finding in our sample that has a strong positive predictive value (PPV) for diagnosing axillary metastasis. Thus, fatty hilum replacement may serve as a reliable marker of axillary metastases. The removal of the fatty hilum, however, reduces diagnostic accuracy when evaluated in conjunction with additional sonographic findings.

The use of FNAB improves the ultrasound's diagnostic accuracy nonetheless the findings may differ based on the quality of the equipment and the sharpness of the pictures and operator expertise is still a crucial element. Consequently, it is recommended to take the biopsy in multiple suspect regions and have a cytologist verify the sample's quality. We conclude that suspicious axillary ultrasounds do not predict positive cytology, as our study shows diagnostics concordances of 26.2% between the ultrasounds and the cytological examination. It is important to consider the cytological study's results in order to reduce the occurrence of false negatives, unsuccessful operations, or insufficient results. Core needle biopsy (CNB) has been found to be more effective than FNAB in terms of sensitivity and number of repeated biopsies but it has also been associated with a larger number of problems. However this risk can be mitigated by ensuring that the personnel performing the surgery are well trained^[14,24]. "Axilla surgery decisions have been

impacted by the worldwide acceptance of the ACOSOG 20011 study since its release. The majority of patients (97.75%) in our study exhibited non-palpable axillary disease and T1-T2 lesions. Because using FNAB as an indicator of ALND can increase its use by up to 20.8% the results of this study allow us to propose the following change in the axillary ultrasound approach instead of using it to diagnose all patients with axillary metastasis, it should only be used in patients with a high burden of tumor disease in the axilla"^[25,14,26,27].

Some axillary lymph node ultrasonographic results were not noted in clinical records, which is a limitation of our retrospective analysis. This study emphasizes the significance of developing standardized criteria for evaluating axillary lymph nodes in a prospective manner.

CONCLUSION

Although axillary ultrasonography is a widely accessible diagnostic tool the results of this study at the Cancer Institute are inconclusive regarding its effectiveness as the primary method for "determining nodal status prior to surgery in patients with breast cancer who do not exhibit clinical evidence of axillary disease. The study found several drawbacks, including low sensitivity and dubious clinical utility. The only ultrasonographic findings of axillary lymph nodes with high positive predictive value (PPV) should be relied upon in order to maximize the utility of axillary ultrasound. By reducing pointless procedures and guaranteeing more accurate preoperative assessments in the treatment of patients with breast cancer, this strategy seeks to improve the study's accuracy. Understanding the function of axillary ultrasonography in the comprehensive care of patients with breast cancer may be improved by more study and protocol improvement."

REFERENCES

1. Nori, J., E. Vanzi, M. Bazzocchi, F.N. Bufalini, V. Distanti, F. Branconi and T. Susini, 2007. Role of axillary ultrasound examination in the selection of breast cancer patients for sentinel node biopsy. *The Am. J. Surg.*, 193: 16-20.
2. Lee, B., A.K. Lim, J. Krell, K. Satchithananda, R.C. Coombes, J.S. Lewis and J. Stebbing, 2013. The efficacy of axillary ultrasound in the detection of nodal metastasis in breast cancer. *Am. J. Roentgenology*, Vol. 200 .10.2214/ajr.12.9032.
3. Üreyen, O., D.K. Çavdar, Z.H. Adibelli and E. İlhan, 2018. Axillary metastasis in clinically node-negative breast cancer. *J. Egypt. Nat. Cancer Inst.*, 30: 159-163.
4. Almeray, T., D. Villacreses, Z. Li, B. Patel and M. McDonough *et al.*, 2019. Value of axillary

- ultrasound after negative axillary mri for evaluating nodal status in high-risk breast cancer. *J. Am. Coll. Surgeons*, 228: 792-797.
5. Balasubramanian, I., C.A. Fleming, M.A. Corrigan, H.P. Redmond, M.J. Kerin and A.J. Lowery, 2018. Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis. *Br. J. Surg.*, 105: 1244-1253.
6. Whitman, G.J., T.J. Lu, M. Adejolu, S. Krishnamurthy and D. Sheppard, 2011. Lymph node sonography. *Ultrasound Clin.*, 6: 369-380.
7. Keelan, S., A. Heeney, E. Downey, A. Hegarty, T. Roche, 2021. Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis. *Breast. Cancer. Res. Treat.*, 187: 303-310.
8. AE, G., H. KK B. and KV 2011. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. *Ann. Surg.*, 11: 305-569.
9. U V, G V, G P. 2010. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. *Ann. Surg.*, 1: 251-595.
10. Cárdenas-Sánchez, J., A.A. Erazo-Valle-Solís, C. Arce-Salinas, E. Bargalló-Rocha and V.B. Piña *et al.*, 2022. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. octava revisión. colima 2019. *Gaceta. Mexicana. Oncolog. A.*, 18: 1-141.
11. McCartan, D., M. Stempel, A. Eaton, M. Morrow and M. Pilewskie, 2016. Impact of body mass index on clinical axillary nodal assessment in breast cancer patients. *Ann. Surg. Oncol.*, 23: 3324-3329.
12. Hanko-Bauer, O., C. Podoleanu, R. Georgescu and S. Stolnicu, 2019. The accuracy of the preoperative axillary ultrasound examination in predicting the status of the sentinel lymph node involvement in patients with infiltrating breast carcinoma. *Chirurgia.*, 114: 384.
13. Sharma, N., 2017. Axillary nodal staging with contrast-enhanced ultrasound. *Springer. Open. Choice.*, 2: 259-263.
14. Park, V.Y., E.K. Kim, H.J. Moon, J.H. Yoon and M.J. Kim, 2018. Value of ultrasound-guided fine needle aspiration in diagnosing axillary lymph node recurrence after breast cancer surgery. *Am. J. Surg.*, 216: 969-973.
15. Cowher, M.S., K.M. Erb, W. Poller and T.B. Julian, 2008. Correlation of the use of axillary ultrasound and lymph node needle biopsy with surgical lymph node pathology in patients with invasive breast cancer. *The Am. J. Surg.*, 196: 756-759.
16. Ramanand, S., B. Ghongane, J. Ramanand, M. Patwardhan, R. Ghanghas and S. Jain, 2013. Clinical characteristics of polycystic ovary syndrome in Indian women. *Indian J. Endocrinol. Metab.*, 17: 138-145.
17. Bravo, R.J. and C. Ly, 2015. Electronic-coupled generators short circuit impacts. 2015 Seventh Annual IEEE Green Technol. Conf., 1: 158-161.
18. Davis, J.T., Y.M. Brill, S. Simmons, B.C. Sachleben and M.L. Cibull *et al.*, 2006. Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis. *Ann. Surg. Oncol.*, 13: 1545-1552.
19. Goel, G., P.D. Janaki, N.V. Smitha, R. Anupama, P.S. Sundaram, Y.S. Nataraj and D.K. Vijaykumar, 2016. Role of axillary ultrasound, fine needle aspiration cytology and sentinel lymph node biopsy in clinically no breast cancer. *Indian J. Surg. Oncol.*, 7: 407-412.
20. Abe, H., R.A. Schmidt, K. Kulkarni, C.A. Sennett, J.S. Mueller and G.M. Newstead, 2009. Axillary lymph nodes suspicious for breast cancer metastasis: Sampling with us-guided 14-gauge core-needle biopsy—clinical experience in 100 patients. *Radiology.*, 250: 41-49.
21. van Wely, B.J., J.H.W. de Wilt, C. Francissen, S. Teerenstra and L.J.A. Strobbe, 2014. Meta-analysis of ultrasound-guided biopsy of suspicious axillary lymph nodes in the selection of patients with extensive axillary tumour burden in breast cancer. *Br. J. Surg.*, 102: 159-168.
22. Bae, M.S., S.U. Shin, S.E. Song, H.S. Ryu, W. Han and W.K. Moon, 2017. Association between us features of primary tumor and axillary lymph node metastasis in patients with clinical t1–t2n0 breast cancer. *Acta Radiol.*, 59: 402-408.
23. Donker, M., G. van Tienhoven, M.E. Straver, P. Meijnen and C.J.H.V. Velde *et al.*, 2014. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (eortc 10981-22023 amaro): A randomised, multicentre, open-label, phase 3 non-inferiority trial. *The Lancet Oncol.*, 15: 1303-1310.
24. Giuliano, A.E., 2011. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. *JAMA*, 305: 569.